Magic Empire Glb 株価情報 (NASDAQ: MEGL)

最新ニュース Magic Empire Glb (NASDAQ:MEGL) 株価情報

Magic Empire Global

Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.

Magic Empire Global Limited - Class A Ordinary Shares

Magic Empire Global Ltd

DLH Holdings Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/DLHC#NASDAQ">DLHC</a>) ("DLH" or the "Company"), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security, today announced that it has been awarded a five year task order valued at up to $37.7 million to continue delivering scientific research and development (R&amp;D), modeling &amp; simulation, artificial intelligence, machine learning, robotic process automation, biomedical engineering, and cloud-enabled big data analytic solutions for the Telemedicine and Advanced Technology Research Center ("TATRC"), a direct reporting unit of the US Army Medical Research &amp; Development Command ("MRDC"). As a hub for developing next generation medical concepts and capabilities, TATRC &amp; MRDC are focused on fusing data, humans, and machines to improve the medical outcomes of military service members around the world.

News

DLHC

DLH Holdings Awarded 5-Yr Task Order Valued At Up To $37.7M To Continue Delivering Scientific R&D And Advanced Technology Services For TATRC

Earnings

Earnings Beats

PARA

Paramount Global Q1 Adj. EPS $0.29 Beats $0.25 Estimate, Sales $7.19B Beat $7.09B Estimate

Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.25 by 32 percent. This is a 26.92 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $616.02 million which beat the analyst consensus estimate of $584.27 million by 5.43 percent. This is a 25.40 percent increase over sales of $491.25 million the same period last year.

Trade Desk Q1 Adj. EPS $0.33 Beats $0.25 Estimate, Sales $616.02M Beat $584.27M Estimate

Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 55 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $9.79 million which beat the analyst consensus estimate of $9.37 million by 4.57 percent. This is a 5.44 percent increase over sales of $9.29 million the same period last year.

TKNO

Alpha Teknova Q1 EPS $(0.09) Beats $(0.12) Estimate, Sales $9.79M Beat $9.37M Estimate

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has nearly achieved 50% enrollment in the initial randomized portion of its Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma, with treatment sites reporting that the drug has been well tolerated and toxicity no greater than 2 on a scale of 1-5. Further, 84% of the enrolled patients have completed all seven cycles. Shuttle has begun analyzing pharmacokinetic/pharmacodynamic samples to compare the relationship between dose and response in terms of the extent and duration of Ropidoxuridine's action. Our objective is to finalize enrollment later this year with follow up and data read out in 2026.
"We are incredibly encouraged by the expedited progress of our Phase 2 trial and the dedication of our team, clinical partners, and patients who are making this milestone possible," commented Shuttle Pharma's Chairman and Chief Scientific Officer, Anatoly Dritschilo, M.D. "If approved, we believe that Ropidoxuridine has the potential to redefine the standard approach for how to care for patients with glioblastoma."
Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle Pharma previously received Orphan Drug Designation from the FDA, providing Shuttle Pharma with potential marketing exclusivity upon obtaining FDA approval for treatment of this disease.
The Phase 2 clinical trial design initially randomizes 40 patients into two different dose levels of drug, with 20 patients receiving 1,200 mg/day and 20 patients receiving 960 mg/day, to determine an optimal dose for use in glioblastoma patients in combination with RT. After the optimal dose is identified, 14 additional patients will be enrolled at the optimal dose to reach statistical significance with the end-point demonstrating increased survival as compared to historical controls.
The Phase 2 clinical trial is conducted at Georgetown University Medical Center, Allegheny Health Network (AHN) Cancer Institute, UNC Medical Center, the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, and Miami Cancer Institute, part of Baptist Health South Florida.
"This clinical trial is critical to the broader radiation therapy industry as we look to leverage radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to continued trial execution as we aim to improve the lives of millions of patients impacted by cancer and to bring hope to patients and families around the world," Dr. Dritschilo concluded.
An estimated 800,000 patients in the US are treated with radiation therapy for their cancers yearly. According to the American Cancer Society and the American Society of Radiation Oncologists, about 50% are treated for curative purposes and the balance for palliative therapeutic care. The market opportunity for radiation sensitizers lies with the 400,000 patients treated for curative purposes, with this number expected to grow by more than 22% over the next five years.

Biotech

General

SHPH

Shuttle Pharma Announces FDA Orphan-Drug Nears Patient Enrollment Milestone For Phase 2 Clinical Trial

Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.29 by 37.93 percent. This is a 90.48 percent increase over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $2.99 billion which missed the analyst consensus estimate of $3.01 billion by 0.88 percent. This is a 3.43 percent increase over sales of $2.89 billion the same period last year.

Earnings Misses

EXPE

Expedia Group Q1 Adj. EPS $0.40 Beats $0.29 Estimate, Sales $2.99B Miss $3.01B Estimate

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) reported quarterly earnings of $1.02 per share which beat the analyst consensus estimate of $0.80 by 27.5 percent. This is a 39.73 percent increase over earnings of $0.73 per share from the same period last year. The company reported quarterly sales of $569.00 million which beat the analyst consensus estimate of $543.40 million by 4.71 percent. This is a 28.82 percent increase over sales of $441.70 million the same period last year.

PODD

Insulet Q1 Adj. EPS $1.02 Beats $0.80 Estimate, Sales $569.00M Beat $543.40M Estimate

Contracts

VREX

Varex Imaging Received Orders For Non-Intrusive Cargo Inspection Systems For ~$25M

Flux Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.07) by 71.43 percent. This is a 25 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $16.74 million which beat the analyst consensus estimate of $16.50 million by 1.47 percent. This is a 15.81 percent increase over sales of $14.46 million the same period last year.

FLUX

Flux Power Holdings Q3 EPS $(0.12) Misses $(0.07) Estimate, Sales $16.74M Beat $16.50M Estimate

Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.27 by 7.41 percent. This is a 53.23 percent decrease over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $7.19 billion which beat the analyst consensus estimate of $7.10 billion by 1.24 percent. This is a 6.42 percent decrease over sales of $7.68 billion the same period last year.

PARAA

Paramount Global Q1 Adj. EPS $0.29 Beats $0.27 Estimate, Sales $7.19B Beat $7.10B Estimate

Akamai Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $1.57 by 8.28 percent. This is a 3.66 percent increase over earnings of $1.64 per share from the same period last year. The company reported quarterly sales of $1.01 billion which met the analyst consensus estimate. This is a 2.84 percent increase over sales of $986.97 million the same period last year.

AKAM

Akamai Techs Q1 Adj. EPS $1.70 Beats $1.57 Estimate, Sales $1.01B Inline

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 15 years by 6.39% on an annualized basis producing an average annual return of 17.69%. Currently, Blackstone has a market capitalization of $108.96 billion. 
Buying $1000 In BX: If an investor had bought $1000 of BX stock 15 years ago, it would be worth $10,842.31 today based on a price of $140.95 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746734514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Blackstone Stock In The Last 15 Years

Curaleaf Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CURA#TSX">CURA</a>) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $310.01 million which missed the analyst consensus estimate of $316.08 million by 1.92 percent. This is a 8.53 percent decrease over sales of $338.93 million the same period last year.

TSX:CURA

Curaleaf Holdings Q1 EPS $(0.07), Inline, Sales $310.01M Miss $316.08M Estimate

Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) affirms FY2025 sales outlook from $725.00 million-$765.00 million to $725.00 million-$765.00 million vs $752.21 million estimate.

Guidance

PCRX

Pacira BioSciences Affirms FY2025 Sales Guidance of $725.00M-$765.00M vs $752.21M Est

Clearfield (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLFD#NASDAQ">CLFD</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.19) by 147.37 percent. This is a 122.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $47.17 million which beat the analyst consensus estimate of $38.52 million by 22.43 percent. This is a 27.79 percent increase over sales of $36.91 million the same period last year.

CLFD

Clearfield Q2 EPS $0.09 Beats $(0.19) Estimate, Sales $47.17M Beat $38.52M Estimate

Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares climbed 3.9% to $192.72 on Thursday following the announcement of a landmark trade agreement between the U.S. and the U.K.
What To Know: A key component of the deal is the <a href="https://www.benzinga.com/politics/25/05/45293839/trump-starmer-strike-us-uk-trade-deal-steel-cars-beef">U.K.&#8217;s pledge</a> to purchase $10 billion worth of Boeing aircraft, fueling investor optimism about Boeing's international order pipeline and overall revenue outlook.
The agreement also includes <a href="https://www.benzinga.com/politics/25/05/45293839/trump-starmer-strike-us-uk-trade-deal-steel-cars-beef">tariff reductions</a> across several sectors, notably a cut in U.S. tariffs on U.K.-made cars from 25% to 10%, and the near elimination of tariffs on American beef and ethanol exports.
U.S. Commerce Secretary Howard Lutnick and President Donald Trump highlighted the deal as a major win for American industry. Trump called it "a model for future trade," while suggesting further deals with China and the EU are imminent. 
The market <a href="https://www.benzinga.com/25/05/45294428/wall-street-rallies-after-us-seals-first-trade-deal-you-better-go-out-and-buy-stock-trump-says">responded positively</a>, with the S&amp;P 500 and Russell 2000 both posting strong gains. Boeing was among the top industrial performers, bolstered further by comments that Rolls-Royce jet engines will now be exported tariff-free for Boeing aircraft.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45285797/forget-rate-cuts-this-year-bank-of-america-warns-after-powells-hawkish-tone">Forget Rate Cuts This Year, Bank Of America Warns After Powell&#8217;s Hawkish Tone</a>
Investors likely viewed the agreement as a sign of strengthening transatlantic ties and improving prospects for U.S. exporters amid a pivot in global trade dynamics.
What Else: Boeing shares also rose Thursday after Taiwan's China Airlines ordered <a href="https://www.benzinga.com/news/contracts/25/05/45290030/boeings-secures-order-from-taiwans-china-airlines">14 fuel-efficient 777X aircraft</a>, becoming the first in Taiwan to do so, with plans to use them for long-haul routes to North America and Europe. 
Meanwhile, Boeing faces halted deliveries to China amid escalating U.S.-China trade tensions and steep tariffs, highlighting its central role in the trade dispute.
<h1 class="wp-block-heading">How To Buy BA Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Boeing&#8217;s case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BA has a 52-week high of $196.95 and a 52-week low of $128.88.
Read Also: • <a href="https://www.benzinga.com/government/regulations/25/05/45277106/trumps-air-force-one-delayed-until-2027-as-boeing-struggles-with-trade-offs-air-force-official-tells-lawmakers">Trump&#8217;s Air Force One Delayed Until 2027 As Boeing Struggles With Trade-Offs, Air Force Official Tells Lawmakers</a>
Photo: Shutterstock

Travel

Global

Movers

Boeing Stock Rises On $10 Billion UK Aircraft Deal in Landmark Trade Pact

MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $2687.0, a high estimate of $3100.00, and a low estimate of $2300.00. This upward trend is evident, with the current average reflecting a 11.44% increase from the previous average price target of $2411.11.
<img src="https://www.benzinga.com/files/images/story/2025/1746734481_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive MercadoLibre. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$3100.00</td>
<td>$2500.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$2400.00</td>
<td>$3000.00</td>
</tr>
<tr>
<td>Fawne Jiang</td>
<td>Benchmark</td>
<td>Announces</td>
<td>Buy</td>
<td>$2500.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Ruben</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$2560.00</td>
<td>$2650.00</td>
</tr>
<tr>
<td>Irma Sgarz</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$2750.00</td>
<td>$2400.00</td>
</tr>
<tr>
<td>Marcelo Santos</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2300.00</td>
<td>$1950.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$3000.00</td>
<td>$2150.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$2760.00</td>
<td>$2350.00</td>
</tr>
<tr>
<td>Robert Ford</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$3000.00</td>
<td>$2500.00</td>
</tr>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$2500.00</td>
<td>$2200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to MercadoLibre. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MercadoLibre compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for MercadoLibre's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of MercadoLibre's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MELI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MercadoLibre analyst ratings.</a>
<h2>Get to Know MercadoLibre Better</h2>
MercadoLibre runs the largest e-commerce marketplace in Latin America, with more than 218 million active users and 1 million active sellers across 18 countries stitching into its commerce network or fintech solutions when last reported. The company operates a host of complementary businesses to its core online shop, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago and Mercado Credito), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
<h3>MercadoLibre: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, MercadoLibre showcased positive performance, achieving a revenue growth rate of 37.42% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: MercadoLibre's net margin excels beyond industry benchmarks, reaching 10.55%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): MercadoLibre's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.3% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): MercadoLibre's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.67%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.57, MercadoLibre faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

MELI

Where MercadoLibre Stands With Analysts

Canfor Pulp Products (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CFX#TSX">CFX</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.10 by 10 percent. This is a 325 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $196.20 million which beat the analyst consensus estimate of $185.93 million by 5.52 percent. This is a 11.74 percent decrease over sales of $222.30 million the same period last year.

TSX:CFX

Canfor Pulp Products Q1 Adj. EPS $0.09 Misses $0.10 Estimate, Sales $196.20M Beat $185.93M Estimate

Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.60 by 3.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $168.92 million which missed the analyst consensus estimate of $176.03 million by 4.03 percent. This is a 1.08 percent increase over sales of $167.12 million the same period last year.

Pacira BioSciences Q1 Adj. EPS $0.62 Beats $0.60 Estimate, Sales $168.92M Miss $176.03M Estimate

In the last three months, 10 analysts have published ratings on Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $88.4, a high estimate of $105.00, and a low estimate of $69.00. Marking an increase of 2.43%, the current average surpasses the previous average price target of $86.30. 
<img src="https://www.benzinga.com/files/images/story/2025/1746734470_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Dollar General's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$93.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$101.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$69.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dollar General. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Dollar General compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Dollar General's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dollar General analyst ratings.</a>
<h2>All You Need to Know About Dollar General</h2>
With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged food, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.
<h3>A Deep Dive into Dollar General's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Dollar General's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.52% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Dollar General's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 1.86%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Dollar General's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.59%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.61%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Dollar General's debt-to-equity ratio stands notably higher than the industry average, reaching 2.36. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Dollar General Stock

Press Releases

Magic Empire Global Limited Announces Receipt of Nasdaq Notification of additional 180 calendar day period to regain compliance of minimum bid price requirement

Magic Empire Global Limited Announces First Half 2024 Unaudited Financial Results

Magic Empire Global Limited announces that the bid price deficiency concern raised by Nasdaq has been successfully resolved

MEGL

AMTD IDEA Group American Depositary Shares, each representing six (6) Class A Ordinary Shares

Comments

Magic Empire Glb

ニュース

最新ニュース Magic Empire Glb (NASDAQ:MEGL) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル